Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. EPAC design and functionalization.
  • Fig. S2. EPAC-captured EV characterization.
  • Fig. S3. Western blot analysis of isolated EVs from SK-MEL-28 and MCF7 cells.
  • Fig. S4. Performance evaluation of the anti-CD63, anti-CD9, or anti-CD81 functionalized EPAC for detection of MCSP-positive EVs from SK-MEL-28 cells.
  • Fig. S5. Monitoring the changes of individual biomarker levels in EVs from drug-treated melanoma cell lines, using the anti-CD63 functionalized EPAC.
  • Fig. S6. Effect of cell debris on the anti-CD63 functionalized EPAC performance.
  • Fig. S7. Anti-MCSP functionalized EPAC specificity.
  • Fig. S8. The ErbB3 expression in EVs derived from melanoma patient (P1 to P10) and normal plasma (H1 to H5) samples, measured with a commercial ELISA kit.
  • Fig. S9. The anti-MCSP functionalized EPAC for tracking EV phenotypic changes of patients 18 to 23 during targeted therapies.
  • Table S1. The anti-MCSP functionalized EPAC for measurements of plasma EVs from 12 healthy donors (H1 to H12) and 8 melanoma patients (P16 to P23).
  • Table S2. Demographic data for melanoma patients and healthy donors.

Download PDF

Files in this Data Supplement: